ORAL DRUG ABUSE: DETERMINANTS AND CONSEQUENCES

过量口服药物的决定因素和后果自我- 将探索按时间表给药诱导的烦渴， 强调口服可卡因（COC）和苯二氮卓类（BZ）滥用变量， 精细运动表现的后果：（A：COC）（1）改善 通过急性和慢性治疗过量COC摄入， 治疗剂（例如，地昔帕明，马吲哚）和（2）替代品 COC摄入（例如，其他解决方案，活动轮）。 （三） 注射尼古丁（NIC）和咖啡因加重COC滥用 （CAF）。 (4)通过首先建立一个 合法药物多饮史（NIC，CAF），（5）可能的行为 针对COC滥用的免疫（情景替代的历史） 采集 急性和慢性注射的后果， 撤回COC用于区分运动性能，以及COC 与NIC和CAF的交互。 （B：BZ）（1）改善过度 通过阻断剂摄入BZ（Ro 15-1788，CGS 8216）和（2）通过 CAF或镇静剂（乙醇）滥用史。 (3)急性和慢性药物 抗焦虑作用的评价，采用夸大的 这类药剂对NaCl溶液的摄取。 (3)精细运动控制 从长期暴露于咪达唑仑的每日反弹的后果（例如，作为 可能被反向激动剂[FG 7142]探针夸大）和咪达唑仑- CAF相互作用。 对于COC和BZ，血清药物和 代谢物将被测量，无论是相对于慢性量滥用 以及与运动表现中断相关的水平。

The determinants and consequences of excessive oral drug self- administration by schedule-induced polydipsia will be explored, emphasizing oral cocaine (COC) and benzodiazepine (BZ) abuse variables and fine-motor performance consequences: (A: COC) (1) The amelioration of excessive COC intake by acute and chronic treatment with possible therapeutic agents (e.g., desipramine, mazindol) and by (2) alternatives to COC ingestion (e.g., other solutions, activity wheel). (3) Exacerbation of COC abuse by injections of nicotine (NIC) and caffeine (CAF). (4) The gateways to exacerbated COC abuse by first instituting a history of licit-drug polydipsia (NIC, CAF), and (5) possible behavioral immunization (history of situational alternatives) against COC abuse acquisition. The consequences of acute and chronic injection and withdrawal of COC for discriminative motor performance, as well as COC interactions with NIC and CAF. (B: BZ) (1) The amelioration of excessive BZ intake by blockers (Ro 15-1788, CGS 8216) and (2) its exacerbation by CAF or a history of sedative (ethanol) abuse. (3) Acute and chronic drug anxiolytic action evaluation by a method employing the exaggerated ingestion of NaC1 solutions by such agents. (3) The fine motor control consequences of daily rebound from chronic exposure to midazolam (e.g., as perhaps exaggerated by inverse agonist [FG 7142] probes) and of midazolam- CAF interactions. For both COC and BZs, serum levels of drug and metabolites will be measured, both with respect to chronic amounts abused and the levels associated with motor performance disruption.